Effect of Process Factors on the Properties of Doxycycline Nanovesicles

被引:16
作者
Honary, S. [1 ]
Zahir, F. [1 ]
机构
[1] Mazandaran Univ Med Sci, Sch Pharm, Pharmaceut Sci Res Ctr, Sari, Iran
关键词
Doxycicline; Vesicles; Drug delivery; Ascorbyl palmitate; Niosomes; NIOSOMES;
D O I
10.4314/tjpr.v11i2.1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To develop and evaluation ascorbyl palmitate niosomes in order to achieve a transdermal and/or systemic nanocarier of doxycycline. Methods: Vesicles were formed from ascorbyl palmitate in combination with cholesterol and a negatively charged lipid, dicetyl phosphate. Niosomes were prepared by film hydration method followed by sonication in which aqueous doxycycline solution (in phosphate buffered saline) was encapsulated in the aqueous regions of the vesicles. The vesicles were evaluated for entrapment and in vitro release as well as for their thermal properties and shape by ultraviolet spectroscopy (UV), differential scanning calorimetry (DSC) and scanning electron microscopy (SEM), respectively. The effect of process conditions - sonication time, pH, hydration temperature and centrifuge speed - on niosome properties was investigated. Results: DSC of pure lipids, vesicles dispersion and mixture of lipids confirmed the formation of niosomes. Other results show that >90% of drug was entrapped in the vesicles and the vesicles were spherical in shape. Drug release from the vesicles was slow (<60% after 8 h). Nanovesicle size was significantly (p < 0.05) affected by sonication time and hydration pH. Although hydration temperature of 100 degrees C promoted the production of smaller vesicles, this temperature would likely cause drug degradation. Conclusion: The use of ascorbyl palmitate along with cholesterol and a charge inducer (dicetyl phosphate) yielded vesicles that satisfactorily encapsulated doxycycline solution. The resulting system can be applied for the formulation of doxycycline niosomes.
引用
收藏
页码:169 / 175
页数:7
相关论文
共 16 条
[1]   Pharmacokinetics of doxycycline in sheep after intravenous and oral administration [J].
Castro, Luis J. ;
Sahagun, Ana M. ;
Jose Diez, M. ;
Fernandez, Nelida ;
Sierra, Matilde ;
Garcia, Juan J. .
VETERINARY JOURNAL, 2009, 180 (03) :389-395
[2]   Tetracycline and Niacinamide in the treatment of blistering skin diseases [J].
Chaidemenos, GC .
CLINICS IN DERMATOLOGY, 2001, 19 (06) :781-785
[3]   Ascorbyl palmitate vesicles (Aspasomes): formation, characterization and applications [J].
Gopinath, D ;
Ravi, D ;
Rao, BR ;
Apte, SS ;
Renuka, D ;
Rambhau, D .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 271 (1-2) :95-113
[4]   1-O-alkylglycerol vesicles (Algosomes):: their formation and characterization [J].
Gopinath, D ;
Ravi, D ;
Rao, BR ;
Apte, SS ;
Rambhau, D .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 246 (1-2) :187-197
[5]   Slow release antibiotics for treatment of septic arthritis in large animals [J].
Haerdi-Landerer, M. Christina ;
Habermacher, Judith ;
Wenger, Barbara ;
Suter, Maja M. ;
Steiner, Adrian .
VETERINARY JOURNAL, 2010, 184 (01) :14-20
[6]   Reactive arthritis or post-infectious arthritis? [J].
Hannu, Timo ;
Inman, Robert ;
Granfors, Kaisa ;
Leirisalo-Repo, Marjatta .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2006, 20 (03) :419-433
[7]   Formulation and characterization of doxorubicin nanovesicles [J].
Honary, S. ;
Ebrahimi, P. ;
Tabbakhian, M. ;
Zahir, F. .
JOURNAL OF VACUUM SCIENCE & TECHNOLOGY B, 2009, 27 (03) :1573-1577
[8]   Proniosomes: A novel drug carrier preparation [J].
Hu, CJ ;
Rhodes, DG .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 185 (01) :23-35
[9]   Doxycycline-induced inhibition of prolidase activity in human skin fibroblasts and its involvement in impaired collagen biosynthesis [J].
Karna, E ;
Palka, J ;
Wolczynski, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 430 (01) :25-31
[10]   Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes [J].
Mokhtar, Mahmoud ;
Sammour, Omaima A. ;
Hammad, Mohammed A. ;
Megrab, Nagia A. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 361 (1-2) :104-111